Skip to main content
BPH ENERGY LTD logo

BPH ENERGY LTD — Investor Relations & Filings

Ticker · BPH ISIN · AU000000BPH4 ASX Financial and insurance activities
Open in API
Filings indexed 1,483 across all filing types
Latest filing 2008-02-12 Interim / Quarterly Rep…
Country AU Australia
Listing ASX BPH

About BPH ENERGY LTD

https://www.bphenergy.com.au/

BPH Energy Ltd is a diversified investment company focused on the commercialization of biomedical technologies and the exploration of energy resources. The company maintains a significant portfolio in the biotechnology sector, notably through its investment in Cortical Dynamics Ltd, which develops the Brain Anaesthesia Response Monitor (BARM) for objective measurement of anesthetic effect. In the energy sector, BPH Energy holds a substantial interest in Advent Energy Ltd, an unlisted oil and gas exploration company with assets including the PEP 11 permit in the offshore Sydney Basin. Additionally, the company has expanded its focus into sustainable energy through investments in Clean Hydrogen Technologies, which utilizes proprietary processes to produce turquoise hydrogen and solid carbon. BPH Energy aims to identify and develop high-growth opportunities within the healthcare and resource sectors to create long-term value.

Recent filings

Filing Released Lang Actions
Half Year Report and Accounts 19 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D Half Year Financial Report For the half year ended 31 December 2007' and contains detailed financial statements including consolidated income statement, balance sheet, statement of changes in equity, cash flow statement, notes to the financial statements, directors' report, auditor's independence declaration, and directors' declaration. The report is prepared in accordance with Australian Accounting Standard AASB 134 Interim Financial Reporting, which is the standard for interim or half-year financial reports. The document covers a period shorter than a full fiscal year (half year ended 31 December 2007) and includes substantive financial data and analysis. It is not an announcement or a certification but a full interim financial report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2008
2008-02-12 English
International HLS5 Scientific Publication 1 page ?K
Regulatory Filings Classification · 85% confidence The document is an ASX announcement dated 12 February 2008 from BioPharmica Limited. It discusses the acceptance of a scientific publication in the journal 'Blood' regarding research findings on HLS5 and its role in gene regulation and cell differentiation. The content is focused on scientific research results and publication information rather than financial data, management changes, or regulatory filings. The document is relatively short (2809 characters) and does not contain financial statements, earnings data, or corporate governance information. It is not an announcement of a report publication but rather a scientific publication announcement. None of the specific filing categories directly correspond to scientific publication announcements. The closest fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2008-02-11 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, reconciliation of cash, and compliance statements. The report covers a specific quarter ended 31 December 2007 and includes substantive financial data and analysis. The length of the document (7522 characters) and the detailed financial content indicate it is a financial report rather than a brief announcement or certification. Appendix 4C is a known Australian Securities Exchange (ASX) form used for quarterly reporting by entities admitted on the basis of commitments, which aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q2 2007
2008-01-28 English
Appendix 3B 8 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules related to new securities issuance and quotation. It details the class, number, terms, and purpose of securities issued, along with information about quotation on the ASX. The content is focused on announcing a new issue of shares and related securities, including options, and the application for their quotation on the stock exchange. There are no financial statements, management discussion, or audit information present. The document is a regulatory announcement specific to capital raising and securities issuance. This matches the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes.
2007-12-19 English
AMENDED ANNOUNCEMENT - Encouraging Trial Results 4 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX release dated 18 December 2007 from BioPharmica Limited. It details encouraging clinical trial results for a brain function monitoring technology (BAR Index) developed by an investee company, Cortical Dynamics. The text describes the clinical trial methodology, results, and potential market applications. It is a detailed announcement of clinical trial outcomes and product development progress rather than a formal financial report, regulatory filing, or management discussion. There is no indication that this is an annual report, earnings release, regulatory filing, or other formal financial document. The document is a corporate announcement focused on clinical trial results and product development progress, which fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2007-12-17 English
Encouraging Trial Results for Monitoring Brain Function 4 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX release dated 17 December 2007 from BioPharmica Limited announcing encouraging clinical trial results for a brain function monitoring technology (the BAR Index). It describes the clinical trial methodology, results, and potential market applications. The document is a detailed announcement of trial outcomes and market context rather than a formal financial report or regulatory filing. It does not contain financial statements, management discussion of financial results, or regulatory certifications. It is not a transcript, capital update, or governance document. The content is primarily a clinical trial results announcement and company update to investors and the market. Given the nature of the document as an announcement of clinical trial results and company progress, it best fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2007-12-16 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.